Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is for patients with cancer who have failed potentially curative treatments or for
whose disease a curative treatment does not exist.
OGX-427 is an antisense product that inhibits expression of one of the heat shock proteins.
Decreasing this heat shock protein (Hsp27) should result in down regulation of pathways
implicated in cancer progression and development of resistance to treatment.